Outlook for New CAR-Based Therapies with a Focus on CAR NK Cells: What Lies Beyond CAR-Engineered T Cells in the Race against Cancer
Open accessThe DOI matches its Crossref record; 16 of the 16 references it cites were found in a registry or an index.
Abstract
Chimeric antigen receptor (CAR) engineering of T cells has revolutionized the field of cellular therapy for the treatment of cancer. Despite this success, autologous CAR-T cells have recognized limitations that have led to the investigation of other immune effector cells as candidates for CAR modification. Recently, natural killer (NK) cells have emerged as safe and effective platforms for CAR engineering. In this article, we review the advantages, challenges, and preclinical and clinical research advances in CAR NK cell engineering for cancer immunotherapy. We also briefly consider the feasibility and potential benefits of applying other immune effector cells as vehicles for CAR expression.Significance: CAR engineering can redirect the specificity of immune effector cells, converting them to a much more potent weapon to combat cancer cells. Expanding this strategy to immune effectors beyond conventional T lymphocytes could overcome some of the limitations of CAR T cells, paving the way for safer and more effective off-the-shelf cellular therapy products.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Car t cell immunotherapy for human cancer
June, C. H., O’Connor, R. S., Kawalekar, O. U., Ghassemi, S., & Milone, M. C. (2018) · Science · doi:10.1126/science.aar6711 · Cited by 3,207 · cited 1×
“This strategy has proven effective against B-cell malignancies and is showing promising activity in clinical trials for other hematologic cancers, with the potential for inducing beneficial responses in solid tumors (1).”
BackgroundThe biology of human natural killer-cell subsets
Cooper, M. A., Fehniger, T. A., & Caligiuri, M. A. (2001) · Trends in Immunology · doi:10.1016/s1471-4906(01)02060-9 · Cited by 2,975 · cited 5×
“Sources of CAR NK cells under investigation in the clinic Cell source Advantages Disadvantages Potential for OTS Peripheral blood Mature phenotype Highly functional and cytotoxic Only 5%–10% of PB lymphocytes are NK cells Heterogenous product Not readily available, need donors Yes Cord blood Readily available from glo…”
BackgroundInfluentialUse of CAR-Transduced Natural Killer Cells in CD19-Positive Lymphoid Tumors
Liu, E., Marin, D., Banerjee, P., Macapinlac, H. A., Thompson, P., Basar, R., Nassif Kerbauy, L., Overman, B., Thall, P., Kaplan, M., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa1910607 · Cited by 2,217 · cited 6×
“Some of the obstacles faced in the clinical application of CAR T-cell therapy are cytokine release syndrome (CRS) and immune effector cell–associated neurotoxicity syndrome (ICANS), both of which increase the length of patient hospitalization and the cost of therapy (2).”
BackgroundMethodSelf-citationUp on the tightrope: natural killer cell activation and inhibition
Lanier, L. L. (2008) · Nature Immunology · doi:10.1038/ni1581 · Cited by 1,656 · cited 3×
“Furthermore, upon engagement, NK cells produce IFNγ, which activates the adaptive immune response through its pleiotropic effects on other immune effector cells, such as macrophages and dendritic cells (9).”
BackgroundInducible Apoptosis as a Safety Switch for Adoptive Cell Therapy
Di Stasi, A., Tey, S.-K., Dotti, G., Fujita, Y., Kennedy-Nasser, A., Martinez, C., Straathof, K., Liu, E., Durett, A. G., Grilley, B., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1106152 · Cited by 1,512
Human chimeric antigen receptor macrophages for cancer immunotherapy
Klichinsky, M., Ruella, M., Shestova, O., Lu, X. M., Best, A., Zeeman, M., Schmierer, M., Gabrusiewicz, K., Anderson, N. R., Petty, N. E., et al. (2020) · Nature Biotechnology · doi:10.1038/s41587-020-0462-y · Cited by 1,495 · cited 2×
“Recent preclinical data demonstrate that macrophages can be engineered with a CAR (CAR-Ms) incorporating a CD3ζ intracellular domain to direct their phagocytic activity specifically against tumors (109, 110).”
BackgroundNatural Killer Cells: Development, Maturation, and Clinical Utilization
Abel, A. M., Yang, C., Thakar, M. S., & Malarkannan, S. (2018) · Frontiers in Immunology · doi:10.3389/fimmu.2018.01869 · Cited by 1,150
Macrophages: Development and Tissue Specialization
Varol, C., Mildner, A., & Jung, S. (2015) · Annual Review of Immunology · doi:10.1146/annurev-immunol-032414-112220 · Cited by 962 · cited 1×
“Macrophages (Greek for “big eaters”) are specialized innate immune cells responsible for detecting and engulfing cellular debris, pathogens, and cancer cells (106).”
BackgroundMultiplex genome editing to generate universal CAR T cells resistant to PD1 inhibition
Ren, J., Liu, X., Fang, C., Jiang, S., June, C. H., & Zhao, Y. (2017) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-16-1300 · Cited by 942
Contribution of NK cells to immunotherapy mediated by PD-1/PD-L1 blockade
Hsu, J., Hodgins, J. J., Marathe, M., Nicolai, C. J., Bourgeois-Daigneault, M.-C., Trevino, T. N., Azimi, C. S., Scheer, A. K., Randolph, H. E., Thompson, T. W., et al. (2018) · Journal of Clinical Investigation · doi:10.1172/jci99317 · Cited by 817 · cited 1×
“Other inhibitory molecules under investigation in NK cells include the classic T-cell checkpoints PD-1 and CTLA4 (67, 68).”
Background
Cited by
Natural killer cells in antitumour adoptive cell immunotherapy
Laskowski, T. J., Biederstädt, A., & Rezvani, K. (2022) · Nature Reviews Cancer · doi:10.1038/s41568-022-00491-0 · Cited by 773
Self-citationRoles of natural killer cells in immunity to cancer, and applications to immunotherapy
Wolf, N. K., Kissiov, D. U., & Raulet, D. H. (2023) · Nature Reviews Immunology · doi:10.1038/s41577-022-00732-1 · Cited by 577
Marin, D., Li, Y., Basar, R., Rafei, H., Daher, M., Dou, J., Mohanty, V., Dede, M., Nieto, Y., Uprety, N., et al. (2024) · Nature Medicine · doi:10.1038/s41591-023-02785-8 · Cited by 516
Self-citationCancer organoids 2.0: modelling the complexity of the tumour immune microenvironment
Polak, R., Zhang, E. T., & Kuo, C. J. (2024) · Nature Reviews Cancer · doi:10.1038/s41568-024-00706-6 · Cited by 298
Metadata
- Authors
- Daher, M., & Rezvani, K.
- Venue
- Cancer Discovery
- Published
- 2021-01-01
- Volume
- 11
- Issue
- 1
- Pages
- 45-58
- ISSN
- 2159-8274 (ISSN-L)
- 2159-8290
- OpenAlex
- W3108226967
- Cited by
- 219
- References
- 16
- FWCI
- 9.70
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Outlook for New CAR-Based Therapies with a Focus on CAR NK Cells: What Lies Beyond CAR-Engineered T Cells in the Race against Cancer. https://app.cochat.ai/papers/10.1158/2159-8290.cd-20-0556
- The paper
- Daher, M., & Rezvani, K. (2021). Outlook for New CAR-Based Therapies with a Focus on CAR NK Cells: What Lies Beyond CAR-Engineered T Cells in the Race against Cancer. Cancer Discovery. https://doi.org/10.1158/2159-8290.cd-20-0556
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.